Research in prestigious journal places novel polyp detection system at highest level of performance in AI-aided colonoscopy category
The research validates that MAGENTIQ-COLO is at the highest level of performance in the AI-aided colonoscopy category. (Credit: JAFAR AHMED on Unsplash)
MAGENTIQ-EYE LTD., an Israeli based technology company founded in 2014, announced today that a comprehensive study on the performance of MAGENTIQ-COLO CADe version has been published in the prestigious Lancet Digital Health medical journal.
The study, titled “A novel computer-aided polyp detection system in screening and surveillance colonoscopy: an international multicentre, randomised, tandem trial,” was performed over a period of 14 months across 10 leading medical centers, 31 endoscopists, and 952 screened and enrolled patients.
The research validates that MAGENTIQ-COLO is at the highest level of performance in the AI-aided colonoscopy category. The study shows that MAGENTIQ-COLO increases adenoma detection rate (ADR) by 7% in absolute values. Increased ADR is believed to have a strong connection to the decrease in colorectal cancer (CRC) occurrence and patient mortality. In addition to ADR, the study also measured MAGENTIQ-COLO’s impact on adenoma miss rate (AMR), and showed that with MAGENTIQ-COLO, AMR was 17% lower in absolute values.
“We are honored to be published by Lancet Digital Health, a journal with a phenomenal worldwide reputation for circulating innovative, practice-changing research,” said Dror Zur, Founder & CEO, MAGENTIQ EYE.
“It is important to note that measuring changes in both ADR and AMR in a single study is a novelty. In addition to FDA approval that we received last year, this milestone is a testament to the impact of MAGENTIQ-COLO in advancing the quality of colonoscopy and setting new healthcare standards in order to save more and more lives.”
Source: Company Press Release